Protein Summary
Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), autophagy and endoplasmic reticulum-associated protein degradation (ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding (via UBA domain) to their polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the proteasome (PubMed:15147878). Plays a role in the ERAD pathway via its interaction with ER-localized proteins UBXN4, VCP and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome (PubMed:19822669, PubMed:18307982). Isoform 1, isoform 2 and isoform 3 play a role in unfolded protein response (UPR) by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 and PDIA2 during ER stress (PubMed:18953672). Involved in the regulation of macroautophagy and autophagosome formation; required for maturation of a ...more
- ENST00000257468
- ENSP00000257468
- ENSG00000135018
- ENST00000376395
- ENSP00000365576
- DA41
- PLIC1
- DA41
- DSK2
- UBQN
- XDRP1
- PLIC-1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
virus perturbation | 0.99 | ||
protein domain | 0.97 | ||
transcription factor binding site profile | 0.86 | ||
interacting protein | 0.82 | ||
kinase perturbation | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 133.2 (req: < 5)
Gene RIFs: 61 (req: <= 3)
Antibodies: 327 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 133.2 (req: >= 5)
Gene RIFs: 61 (req: > 3)
Antibodies: 327 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 16
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0